Panel Vice Chair, Massachusetts General Hospital, Boston, Massachusetts.
Research Author, Brigham & Women's Hospital, Boston, Massachusetts.
J Am Coll Radiol. 2021 Nov;18(11S):S442-S455. doi: 10.1016/j.jacr.2021.08.011.
Primary vaginal cancer is rare, comprising 1% to 2% of gynecologic malignancies and 20% of all malignancies involving the vagina. More frequently, the vagina is involved secondarily by direct invasion from malignancies originating in adjacent organs or by metastases from other pelvic or extrapelvic primary malignancies. Data on the use of imaging in vaginal cancer are sparse. Insights are derived from the study of imaging in cervical cancer and have reasonable generalizability to vaginal cancer due to similar tumor biology. Given the trend toward definitive chemoradiation for both cancers in all but early stage lesions, principles of postchemoradiation tumor response evaluation are largely analogous. Accordingly, many of the recommendations outlined here are informed by principles translated from the literature on cervical cancer. For pretreatment assessment of local tumor burden and in the case of recurrent vaginal cancer, MRI is the preferred imaging modality. PET/CT has demonstrated utility for the detection of nodal metastatic and unexpected distant metastatic disease. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
原发性阴道癌较为罕见,占妇科恶性肿瘤的 1%~2%,占所有累及阴道的恶性肿瘤的 20%。阴道更常继发于邻近器官起源的恶性肿瘤的直接侵犯,或来自其他盆腔或盆腔外原发性恶性肿瘤的转移。有关阴道癌影像学应用的数据较少。这些数据来源于对宫颈癌影像学的研究,由于肿瘤生物学相似,因此具有一定的可推广性。鉴于这两种癌症除早期病变外均倾向于采用确定性放化疗,放化疗后肿瘤反应评估的原则在很大程度上是类似的。因此,这里概述的许多建议是基于从宫颈癌文献中翻译过来的原则。对于局部肿瘤负荷的术前评估和复发性阴道癌,MRI 是首选的影像学检查方法。PET/CT 已被证明可用于检测淋巴结转移和意外的远处转移疾病。美国放射学院(ACR)适宜性标准是针对具体临床情况的循证指南,每年由多学科专家小组进行审查。指南的制定和修订包括对同行评议期刊上的现有医学文献进行广泛分析,并应用成熟的方法(RAND/UCLA 适宜性方法和推荐评估、制定和评价分级或 GRADE)对特定临床情况下的影像学和治疗程序的适宜性进行评分。在缺乏证据或证据模棱两可的情况下,专家意见可以补充现有证据,以推荐影像学或治疗。